AION Labs, a new innovation lab spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, has announced a global call for application to identify biomedical scientists and inventors to form a new startup at...
Locus Biosciences has entered a credit facility of up to US$25m with Hercules Capital, which it says will support the expansion of its precision engineered bacteriophage discovery platform engine and in-house manufacturing capacity.
Charles River and ATEM Structural Discovery (ATEM) are collaborating to provide access to cryo-electron microscopy (cryo-EM), a technique that visualizes molecules and proteins in atomic resolution to determine their 3D shape.
The new alliance will focus on the development and manufacturing of complex medicines including biologics, vaccines, nucleic acids and cell and gene therapies; as well as looking to launch companies to advance the manufacture of such medicines.
CureVac is withdrawing its first-generation COVID-19 vaccine candidate, CVnCoV, from regulatory review: instead it is re-allocating its efforts to its second-generation vaccine program with GSK. ‘The goal has not changed, but the requirements to effectively...
AstraZeneca's AZD7442, a long acting antibody (LAAB) combination, achieved a statistically significant reduction in severe COVID-19 or death compared to placebo in non-hospitalised patients with mild-to-moderate symptomatic COVID-19.
Absci Corp, a synthetic biology firm, is partnering with pharma company, EQRx, to jointly engineer and develop several clinical candidates across multiple therapeutic areas, including oncology and immunology.
M Ventures, the strategic, corporate venture capital arm of Merck KGgA, continues to fund iOmx Therapeutics AG, a company developing cancer therapeutics based on next generation immune checkpoint targets.